Skip to content
RecallWatchMedical Device Safety
Class IIOngoingZ-1267-2025

MIM Software Inc recalls MIM software

MIM Software IncCleveland, OH, United StatesReported Mar 12, 2025 · 1 year ago
Legal News Analyst ·

Reason for recall

In situations where two images with differing Fields of View (FOV) complete an image fusion, an incorrect, elevated Maximum Standardized Uptake Value (SUV) within MIM Software versions 7.2.0 through 7.2.6.could result.

Affected product

Check your device

Enter a lot, serial, REF, or UDI number from your device's label to check it against this recall's listed codes.

MIM software; System, Image Processing, Radiological

Lot / code information

Software versions: 1. MIM Anyware 1.1, UDI/DI Not Applicable 2. MIM 7.2.0, UDI/DI 00850009343192; 3. MIM 7.2.1, UDI/DI 00850009343192; 4. MIM 7.2.2, UDI/DI 00850009343192; 5. MIM 7.2.3, UDI/DI 00850009343192; 6. MIM 7.2.4, UDI/DI 00850009343192; 7. MIM 7.2.5, UDI/DI 00850009343192; 8. MIM 7.2.6, UDI/DI 00850009343192

What the firm is doing

GE Healthcare issued an URGENT MEDICAL DEVICE CORRECTION notice to its consignees on 02/19/2025 disseminated using a traceable means. The notice explained the issue, potential risk to the patient, and provided the following actions to be taken to use the device: "You can continue to use your device if you are not using the SUV tool or if you access a non-impacted version of MIM when using the SUV tool. If using a non-default workflow and fusing a PET or SPECT image with another image with a different FOV, do not incorporate the Maximum SUV value into assessment of disease status, progression or response to treatment. NOTE: MIM s default workflows do not fuse images with differing FOV, and the Maximum SUV values reported are correct. If you are using the SUV tool and are unsure if you are affected by this issue, please contact your MIM Site Development Manager, your Distributor for MIM Software, or MIM Customer Support." "Please ensure all potential users in your facility are made aware of this safety notification and the recommended actions."

DistributionShow details

Worldwide distribution - United States Nationwide and the countries of Australia, Belgium, Bolivia, Canada, China, Croatia, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Poland, Russia, Spain, Sweden, United Kingdom, Finland, Hong Kong.

Class IIWhat this means

Use of the product may cause temporary or medically reversible adverse health consequences.

Sources & references

Taylor Coteus
Legal News Analyst

Taylor Coteus is RecallWatch's Legal News Analyst, covering FDA medical-device enforcement and patient-safety litigation. He reviews every recall against the FDA's official openFDA record before it is published and is responsible for corrections and editorial accuracy.

More Class II recalls